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Abstract: Importance There are no established measures to prevent nocturnal breathing disturbances
and other altitude-related adverse health effects (ARAHEs) among lowlanders with chronic obstructive
pulmonary disease (COPD) traveling to high altitude. Objective To evaluate whether nocturnal oxygen
therapy (NOT) prevents nocturnal hypoxemia and breathing disturbances during the first night of a stay
at 2048 m and reduces the incidence of ARAHEs. Design, Setting, and Participants This randomized,
placebo-controlled crossover trial was performed from January to October 2014 with 32 patients with
COPD living below 800 m with forced expiratory volume in the first second of expiration (FEV1) between
30% and 80% predicted, pulse oximetry of at least 92%, not requiring oxygen therapy, and without history
of sleep apnea. Evaluations were performed at the University Hospital Zurich (490 m, baseline) and during
2 stays of 2 days and nights each in a Swiss Alpine hotel at 2048 m while NOT or placebo treatment was
administered in a randomized order. Between altitude sojourns, patients spent at least 2 weeks below
800 m. Data analysis was performed from January 1, 2015, to December 31, 2018. Intervention During
nights at 2048 m, NOT or placebo (room air) was administered at 3 L/min by nasal cannula. Main
Outcomes and Measures Coprimary outcomes were differences between NOT and placebo intervention
in altitude-induced change in mean nocturnal oxygen saturation (SpO2) as measured by pulse oximetry
and apnea-hypopnea index (AHI) measured by polysomnography during night 1 at 2048 m and analyzed
according to the intention-to-treat principle. Further outcomes were the incidence of predefined ARAHE,
other variables from polysomnography results and respiratory sleep studies in the 2 nights at 2048 m,
clinical findings, and symptoms. Results Of the 32 patients included, 17 (53%) were women, with a mean
(SD) age of 65.6 (5.6) years and a mean (SD) FEV1 of 53.1% (13.2%) predicted. At 490 m, mean (SD)
SpO2 was 92% (2%) and mean (SD) AHI was 21.6/h (22.2/h). At 2048 m with placebo, mean (SD) SpO2
was 86% (3%) and mean (SD) AHI was 34.9/h (20.7/h) (P < .001 for both comparisons). Compared with
placebo, NOT increased SpO2 by a mean of 9 percentage points (95% CI, 8-11 percentage points; P <
.001), decreased AHI by 19.7/h (95% CI, 11.4/h-27.9/h; P < .001), and improved subjective sleep quality
measured on a visual analog scale by 9 percentage points (95% CI, 0-17 percentage points; P = .04).
During visits to 2048 m or within 24 hours after descent, 8 patients (26%) using placebo and 1 (4%) using
NOT experienced ARAHEs (P < .001). Conclusions and Relevance Lowlanders with COPD experienced
hypoxemia, sleep apnea, and impaired well-being when staying at 2048 m. Because NOT significantly
mitigated these undesirable effects, patients with moderate to severe COPD may benefit from preventive
NOT during high altitude travel. Trial Registration ClinicalTrials.gov Identifier: NCT02150590
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Abstract
IMPORTANCE There are no establishedmeasures to prevent nocturnal breathing disturbances and
other altitude-related adverse health effects (ARAHEs) among lowlanders with chronic obstructive
pulmonary disease (COPD) traveling to high altitude.
OBJECTIVE To evaluate whether nocturnal oxygen therapy (NOT) prevents nocturnal hypoxemia
and breathing disturbances during the first night of a stay at 2048 m and reduces the incidence
of ARAHEs.
DESIGN, SETTING, AND PARTICIPANTS This randomized, placebo-controlled crossover trial was
performed from January to October 2014 with 32 patients with COPD living below 800mwith
forced expiratory volume in the first second of expiration (FEV1) between 30% and 80% predicted,
pulse oximetry of at least 92%, not requiring oxygen therapy, and without history of sleep apnea.
Evaluations were performed at the University Hospital Zurich (490m, baseline) and during 2 stays of
2 days and nights each in a Swiss Alpine hotel at 2048mwhile NOT or placebo treatment was
administered in a randomized order. Between altitude sojourns, patients spent at least 2 weeks
below 800m. Data analysis was performed from January 1, 2015, to December 31, 2018.
INTERVENTION During nights at 2048m, NOT or placebo (room air) was administered at 3 L/min
by nasal cannula.
MAINOUTCOMESANDMEASURES Coprimary outcomes were differences between NOT and
placebo intervention in altitude-induced change in mean nocturnal oxygen saturation (SpO2) as
measured by pulse oximetry and apnea-hypopnea index (AHI) measured by polysomnography
during night 1 at 2048m and analyzed according to the intention-to-treat principle. Further
outcomes were the incidence of predefined ARAHE, other variables from polysomnography results
and respiratory sleep studies in the 2 nights at 2048m, clinical findings, and symptoms.
RESULTS Of the 32 patients included, 17 (53%) were women, with a mean (SD) age of 65.6 (5.6)
years and a mean (SD) FEV1 of 53.1% (13.2%) predicted. At 490m, mean (SD) SpO2was 92% (2%)
andmean (SD) AHI was 21.6/h (22.2/h). At 2048mwith placebo, mean (SD) SpO2was 86% (3%) and
mean (SD) AHI was 34.9/h (20.7/h) (P < .001 for both comparisons). Compared with placebo, NOT
increased SpO2 by a mean of 9 percentage points (95% CI, 8-11 percentage points; P < .001),
decreased AHI by 19.7/h (95% CI, 11.4/h-27.9/h; P < .001), and improved subjective sleep quality
measured on a visual analog scale by 9 percentage points (95% CI, 0-17 percentage points; P = .04).
(continued)
Key Points
Question Can nocturnal oxygen
therapy prevent hypoxemia and sleep
apnea among lowlanders with chronic
obstructive pulmonary disease when
traveling to high altitude?
Findings In this randomized crossover
trial of 32 lowlanders with chronic
obstructive pulmonary disease,
nocturnal oxygen therapy improved
their mean nocturnal oxygen saturation
and apnea-hypopnea index during a
night at 2048m. Nocturnal oxygen
therapy also reduced the incidence of
altitude-induced adverse health effects
requiringmedical treatment or descent
to lower altitude by 85% compared
with placebo.
Meaning Patients with chronic
obstructive pulmonary disease may
benefit from nocturnal oxygen therapy
during travel to high altitude because it
reduces nocturnal hypoxemia, sleep
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Abstract (continued)
During visits to 2048m or within 24 hours after descent, 8 patients (26%) using placebo and 1 (4%)
using NOT experienced ARAHEs (P < .001).
CONCLUSIONS ANDRELEVANCE Lowlanders with COPD experienced hypoxemia, sleep apnea,
and impaired well-being when staying at 2048m. Because NOT significantly mitigated these
undesirable effects, patients with moderate to severe COPDmay benefit from preventive NOT
during high altitude travel.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02150590
JAMA Network Open. 2020;3(6):e207940. doi:10.1001/jamanetworkopen.2020.7940
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation related
to airway inflammation associated with airway narrowing and destruction of the lung parenchyma.
Given that COPD is highly prevalent and the fourth leading cause of death, it is a major health
problemworldwide.1 Although COPD is a progressive condition, medical treatment may improve
symptoms in many patients. Today, millions of tourists travel to high altitude for leisure or work
activities, and many patients with COPD are among them. Studies have found that acute ascent to
altitude above 2500m causes hypoxemia, periodic breathing, disturbed sleep, and exercise
intolerance in healthy travelers,2,3whereas short-term altitude exposures between 2000m and
2500m (equivalent to pressurized airplane cabins during long-distance flights) seem to be
unproblematic for healthy individuals. However, patients with preexisting lung diseases, such as
COPD, may experience severe hypoxemia at high altitude because of disease-related ventilatory
limitations and impaired gas exchange.4-8 Thus, in a randomized clinical trial among patients with
moderate to severe COPD (ie, forced expiratory volume in the first second of expiration [FEV1]
between 30% and 80% predicted) who were exposed for 2 days at 2590m,4we observed an
incidence of 24% of altitude-related adverse health effects (ARAHEs) requiring medical intervention.
Moreover, endurance of submaximal exercise at this altitude was reduced bymore than half
compared with near sea level,5 and the patients with COPD experienced nocturnal hypoxemia,
frequent sleep apnea,7 and autonomic dysregulation.8 In a randomized, placebo-controlled trial
among 118 lowlanders with COPD,6 preventive dexamethasone treatment improved nocturnal
hypoxemia and sleep apnea during a stay at 3100m; however, dexamethasone did not reduce the
incidence of ARAHEs and induced hyperglycemia. Supplemental oxygen therapy may improve
oxygenation and exercise capacity in patients with COPDwho are acutely exposed to high
altitude.9,10While daytime oxygen administration during mountain outdoor activities is inconvenient
or may be unpractical, nocturnal oxygen therapy (NOT) could be a feasible way to prevent severe
hypoxemia, breathing disturbances, and ARAHEs in patients with COPD during altitude sojourns.
Therefore, the purpose of this randomized, placebo-controlled trial was to evaluate the hypothesis
that NOT would improve nocturnal oxygen saturation and breathing instability as well as reduce the
incidence of ARAHEs in lowlanders with COPD staying at high altitude.
Methods
StudyDesign
This randomized, placebo-controlled, crossover trial was performed from January 1 to October 31,
2014, in patients with COPD living below 800m. During a stay at 2048m, it evaluated the effects of
NOT on the primary outcomes, ie, nocturnal arterial oxygen saturation (SpO2) asmeasured by pulse
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oximetry and breathing disturbances, as well as on several secondary outcomes, including sleep and
ARAHEs. Participants underwent baseline evaluations during 1 day and night at 490m (Zurich,
Switzerland) and had the same evaluations during the course of 2 visits, of 2 days and nights each, in
amountain hotel at 2048m (StMoritz, Switzerland). In the nights at 2048mpatients received either
NOT or placebo (ie, ambient air) according to a randomized crossover trial design. Patients had to
spend at least 2 weeks at low altitude (ie, <800m) between study periods. The protocol was
approved by the cantonal ethics committee Zurich and is available in Supplement 1. Participants gave
written informed content; there was no financial compensation. The trial followed the Consolidated
Standards of Reporting Trials (CONSORT) reporting guideline.
Patients
Patients with COPDwith Global Initiative for Obstructive Lung Disease grades 2 to 3 (ie, FEV1 / forced
vital capacity, <0.7; FEV1, 30% to 80% predicted), aged 18 to 75 years, both sexes, and living at low
altitude (ie, <800m)were invited. Exclusion criteria were hypoxemia of SpO2 lower than 92% at 490
m, home oxygen or CPAP therapy, any uncontrolled cardiovascular disease, or history of obstructive
sleep syndrome. The 5 patients in whom clinical evaluation raised the suspicion of undiagnosed sleep
apnea were evaluated by nocturnal pulse oximetry and were excluded if their oxygen desaturation
index exceeded 15 events/h. No patients were excluded. Further exclusion criteria are described in
the eAppendix in Supplement 2.
Randomization and Intervention
Patients were randomized in balanced blocks of 4 and were assigned to sequences of altitude
exposure and treatment (1-4) by letting them draw a sealed envelope with 1 of the following
allocations: (1) assessment at 490m first, allocated to receive placebo on first trip to 2048m, then
NOT on second trip; (2) assessment at 490m first, allocated to receive NOT on first trip to 2048m,
then placebo on second trip; (3) allocated to receive placebo on first trip to 2048m, then NOT on
second trip, with assessment at 490m last; and (4) allocated to receive NOT on first trip to 2048m,
then placebo on second trip, with assessment at 490m last (Figure 1). Participants traveled by train
and automobile within 3 hours from 490 to 2048 m. Between altitude trips, a washout period of at
least 2 weeks at lower than 800mwas interposed. During 2 nights at 2048m, patients wore nasal
prongs connected to a concentrator (EverFlow, Philips Respironics) delivering oxygen or placebo
(ambient air) at a flow rate of 3 L/min. Patients were masked for the intervention by placing
concentrators in a separate room. Investigators performing the data analysis were also masked to
intervention and exposure sequence. For safety reasons, patients’ nocturnal oxygen saturation was
monitored by investigators, makingmasking of these individuals not feasible.
Assessments
In the first night of each visit, polysomnography (Alice 5, Philips Respironics) was performed,
including transcutaneous capnography and cerebral tissue oxygen saturation monitoring by near-
infrared spectroscopy as described previously (eAppendix in Supplement 2).11-13On the second night
at 2048m, respiratory sleep studies without neurophysiologic channels and near-infrared
spectroscopy were conducted. Sleep stages and arousals were scored according to the
Rechtschaffen and Kales standard14 and American Academy of SleepMedicine guidelines.12 Scoring
of apneas and hypopneas has been described previously (eAppendix in Supplement 2).7 The apnea-
hypopnea index (AHI) was computed as the number of events per hour of total sleep time and time
in bed, and the oxygen desaturation index (>3% SpO2 dips) was computed as the number of events
per hour of time in bed.
Morning evaluations included weight, heart rate, blood pressure, and SpO2. Sleepiness was
evaluated by the Karolinska sleepiness scale15 and the Stanford sleepiness scale.16 Subjective sleep
quality was rated on a 100-mm visual analog scale ranging from 0 (very bad) to 100 (excellent).6
Symptoms of acute mountain sickness (AMS) were evaluated by the Environmental Symptoms
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Questionnaire Cerebral score. Scores of at least 0.7 on the Environmental Symptoms Questionnaire
Cerebral score were considered to reflect clinically relevant AMS.17During the psychomotor vigilance
test, patients were sitting comfortably in a quiet room. They had to press a button on a handheld
device in response to a light on the device flashing at random intervals, andmedian reaction timewas
recorded.18 Arterial blood gas analysis, 6-minute walk testing, and lung function testing, including
single-breath diffusing capacity for carbonmonoxide, were performed in themorning during
ambient air breathing (eAppendix in Supplement 2).19-21
Outcomes
Coprimary outcomes were differences between NOT vs placebo treatment in mean nocturnal SpO2
and AHI from 490m to the first night at 2048 m. Secondary outcomes were additional variables
derived from sleep studies in the 2 nights at 2048m, arterial blood gases, lung function, cognitive
performance, and the incidence of ARAHEs. According to predefined safety precautions, patients
experiencing any ARAHE, including intercurrent illness (eg, exacerbation of COPD, cardiovascular
disease, infection, or new diseases), severe hypoxemia (ie, SpO2 <75% for >30minutes at any time
while at high altitude), AMS (Environmental Symptoms Questionnaire Cerebral score, 0.7), or any
other condition requiring therapy, were treated as appropriate and withdrawn from the study.
Figure 1. Study FlowDiagram
42 Eligible
10 Excluded
6 Refused to participate
1 Other medical conditions
2 Unstable COPD
1 Unstable cardiovascular disease
32 Randomized
7 Allocated to and received
assessment at 490 m
8 Allocated to and received
assessment at 490 m
9 Allocated to 2 nights at 2048 m
with placebo
6 Received allocated intervention
2 Did not receive allocated
intervention due to onset of
cardiovascular disease
1 Did not receive allocated
intervention due to severe
nocturnal hypoxemia
8 Allocated to and received 2 nights
at 2048 m with NOT
6 Allocated to and received 2 nights
at 2048 m with NOT
7 Allocated to 2 nights at 2048 m
with placebo
5 Received allocated intervention
2 Did not receive allocated
intervention due to severe
nocturnal hypoxemia
6 Allocated to and received
assessment at 490 m
6 Allocated to and received
assessment at 490 m
7 Analyzed by intention-to-treat
6 Analyzed by per-protocol
8 Analyzed by intention-to-treat
5 Analyzed by per-protocol
9 Analyzed by intention-to-treat
6 Analyzed by per-protocol
8 Analyzed by intention-to-treat
6 Analyzed by per-protocol
1 With COPD exacerbation
1 With COPD exacerbation
7 Allocated to 2 nights at 2048 m 
with placebo
6 Received allocated intervention
1 Did not receive allocated
intervention due to severe
nocturnal hypoxemia
8 Allocated to and received 2 nights
at 2048 m with NOT
6 Allocated to and received 2 nights
at 2048 m with NOT
8 Allocated to 2 nights at 2048 m 
with placebo
7 Received allocated intervention
1 Did not receive allocated
intervention due to panic attack
at night
Washout of 2 weeks at <800 m
Washout of 2 weeks at <800 m
Altitude allocation sequence and order of intervention (oxygen or placebo) at 2048mwere randomized. After evaluations at 2048m, a 2-week washout period below 800mwas
applied to avoid carry-over effects. COPD indicates chronic obstructive pulmonary disease.
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Sample Size
We aimed to detect differences between NOT and placebo in mean (SD) SpO2 of 2% (4%) and in the
mean (SD) AHI of 10/h (20/h) with a 2-sided α < .05 and a power of 80%. The required sample size
was 32 participants.7
Statistical Analysis
Data analysis was performed from January 1, 2015, to December 31, 2018. The data are summarized
as mean and SD. The coprimary outcomes were analyzed by intention-to-treat, with missing data
replaced bymultiple imputations, and per-protocol.22Data from 4 patients who received NOT
because of severe hypoxemia (SpO2 <75% for >30minutes) during the altitude sojourn with placebo
were included in the intention-to-treat analysis but eliminated from the per-protocol analysis. Mean
values, SEs, mean differences, and 95% CIs betweenmeasures at 490m and at 2048mwith NOT or
placebo from continuous coprimary outcomes SpO2 and AHI and continuous secondary outcomes
were computed using linear mixed models with outcomes as dependent variables and altitude and
intervention as independent variables.23 The proportion of participants experiencing ARAHEs was
evaluated by the Fisher exact test and logistic regression analysis. Exploratory regression analyses
were performed to elucidate low-altitude variables associated with ARAHE, breathing instability, and
nocturnal SpO2 at 2048m. Statistical significance was assumedwhen 95% CIs of mean differences
did not overlap zero. For secondary outcomes and other exploratory analyses, no adjustment of the
significance threshold was performed. Statistical analysis was performed by Stata version 15.1
(StataCorp), and the statistical analysis plan is available in Supplement 1.
Results
A total of 42 patients were assessed for eligibility, and 32 (17 [53%] women and 15 [47%]men), with
amean (SD) age of 65.6 (5.6) years and amean (SD) FEV1 of 53.1% (13.2%) predicted, were included
in the study (Figure 1). The per-protocol analysis included 23 patients. Baseline characteristics are
displayed in Table 1. The participants had moderate to severe COPD, more than half (17 [53%]) had
cardiovascular comorbidities (mainly arterial hypertension and coronary heart disease), and they
were not excessively sleepy, ie, had normal Epworth sleepiness scores (mean [SD], 4.4 [3.3]).
Arterial Oxygenation andAHI
The results of the intention-to-treat analysis of the primary outcomes are illustrated in Figure 2, and
the results of the per-protocol analysis are summarized in Table 2. During both nights at 2048m
with placebo, themean (SD) nocturnal SpO2was significantly decreased (night 1: 86% [3%]; night 2:
87% [3%]) comparedwith values at 490m (night 1: 92% [2%]; P < .001) (Table 2 and Figure 2). The
absolute mean treatment effects during night 1 and 2 with NOT at 2048 mwere 9 (95% CI, 8 to 11)
percentage points and 8 (95% CI, 7 to 10) percentage points, respectively, in the intention-to-treat
analysis (Figure 2). During both nights at 2048 mwith placebo, the mean (SD) total AHI was
significantly increased (night 1: 34.9/h [20.7/h]; night 2: 27.8/h [21.0/h]) comparedwith values at 490
m (nights 1: 21.6/h [22.2/h]; P < .001) because of a major increase in the central AHI (night 1:
difference, 24.9/h; 95% CI, 18.7/h to 31.1/h, P < .001) (Table 2 and Figure 2), while obstructive events
were slightly decreased in comparison with 490m (night 1 difference, −0.3/h; 95% CI, −3.6/h to
3.0/h). With NOT during night 1 and 2 at 2048m, themean treatment effects in total AHI were
−19.7/h (95% CI, −27.9/h to −11.4/h) and −16.3/h (95% CI, −25.1/h to −7.5/h), respectively, in the
intention-to-treat analysis (Figure 2).
Other Indices of Nocturnal Breathing
Correspondingly, in the per-protocol analysis, NOT at 2048m prevented the altitude-induced
increase in central AHI (difference on night 1, −21.5/h; 95% CI, −28.3/h to −14.7/h), periodic breathing
(difference on night 1, −12.4% of time in bed; 95% CI, −17.1% to −7.7% of time in bed), oxygen
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desaturation index (difference on night 1, −35.9/h; 95% CI, −44.4/h to −27.5/h), time spent with SpO2
lower than 90% (difference on night 1, −76.4% of time in bed; 95% CI, −87.5% to −65.3% of time in
bed), and cerebral tissue deoxygenation (difference on night 1, 9 percentage points; 95% CI, 7
percentage points to 11 percentage points) (Table 2). Analysis of groups allocated to different altitude
and drug exposure sequences revealed no order effect for the coprimary outcomes (eTable 1 and
eTable 2 in Supplement 2).
There was an altitude-induced decrease in transcutaneous carbon dioxide in nights with
placebo at 2048m compared with 490m (first night: mean [SD], 4.8 [0.4] kPa vs 5.5 [0.7] kPa;
P < .001); with NOT, a similar decrease was seen on the first but not on the second night at 2048m
compared with 490m (mean [SD], 4.9 [0.8] kPa vs 5.5 [0.7] kPa; P = .01). With placebo, a significant
increase in heart rate during nights at 2048mwas observed comparedwith 490m (first night: mean
[SD] 76 [12] beats/min [bpm] vs 69 [10] bpm; P < .001), but NOT reduced heart rate by −7 bpm (95%
CI, −10 to −5 bpm) in night 1 and −4 bpm (95% CI, −6 to −1 bpm) in night 2 compared with placebo.
Sleep Indices
Compared with values at 490m, receiving a placebo at 2048mwas associated with a decrease in
total sleep time (mean [SD], 400 [61] min vs 349 [76] min; P < .001), proportion of rapid-eye
movement sleep (mean [SD], 15.4% [4.3%] vs 11.9% [6.8%]; P = .004), and sleep efficiency (mean
[SD], 81% [11%] of time in bed vs 72% [15%] of time in bed; P < .001), and an increase in wake time
after sleep onset (mean [SD], 75.3 [49.3] min vs 116.8 [67.8] min; P < .001) and arousal index (mean
[SD], 13.7/h [8.8/h] vs 18.7/h [16.2/h]; P = .03). NOT improved total sleep time (difference on night
1, 35 min; 95% CI, 9 to 61 min), proportion of rapid-eyemovement sleep (difference on night 1, 3.2%
of total sleep time; 95%CI, 0.7% to 5.7%of total sleep time), sleep efficiency (difference on night 1,
7% of time in bed; 95% CI, 2% to 11% of time in bed), and reduced wake time after sleep onset
(difference on night 1, −30.0min; 95% CI, −52.2 to −7.9min) and arousal index (difference on night 1,
−4.6/h; 95% CI, −9.2/h to 0.0/h) (Table 2).
Table 1. Patient Characteristics
Variable
Population, No. (%)
Intention to treat (N = 32) Per protocol (n = 23)
Men 15 (47) 10 (43)
Women 17 (53) 13 (57)
Age, mean (SD), y 65.6 (5.6) 66.0 (5.1)
Smoking
Current 9 (28) 4 (17)
Pack-years, mean (SD) 37.6 (31.5) 38.2 (31.5)
FEV1, % predicted, mean (SD) 53.1 (13.2) 53.7 (12.8)
GOLD grade 2 23 (72) 16 (70)
Body mass index, mean (SD)a 26.0 (4.5) 25.3 (3.9)
Epworth sleepiness scale score, mean (SD) 4.4 (3.3) 4.6 (3.5)
Comorbidities
Cardiovascular disease including hypertension 17 (53) 12 (52)
Diabetes 4 (13) 3 (13)
Depression 5 (16) 3 (13)
Medication
Inhaled glucocorticosteroids 5 (16) 2 (9)
Inhaled β-adrenergics 24 (75) 17 (74)
Inhaled anticholinergics 23 (72) 18 (78)
Diuretics 5 (16) 2 (9)
Antihypertensive medication 17 (53) 12 (52)
Antidiabetics 4 (13) 3 (13)
Antidepressants 5 (16) 3 (13)
Abbreviations: FEV1, forced expiratory volume in the
first second of expiration; GOLD, Global Initiative for
Obstructive Lung Disease.
a Bodymass index calculated as weight in kilograms
divided by height in meters squared.
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Variables AssociatedWithNocturnal Pulse Oximetry andAHI
Linear mixed regressionmodels for AHI and nocturnal SpO2 at 2048m under placebo as dependent
variables revealed that low altitude AHI and nocturnal SpO2 as well as acclimatization (night 2 vs
night 1 at 2048m) were independently associated (eTable 3 and eTable 4 in Supplement 2).
Univariable logistic regression analyses evaluating low-altitude variables associated with ARAHE
included age, sex, bodymass index, lung function outcomes, arterial blood gases, and 6-minute walk
distance. However, none of the variables was associated with ARAHEs (eTable 5 in Supplement 2).
ARAHEs
During altitude sojourns or within the first 24 hours after descent, 8 of 31 patients (26%) using
placebo and 1 of 28 patients (4%) using NOT experienced ARAHEs (odds ratio of NOT vs placebo,
0.10; 95% CI 0.01 to 0.88; P = .04). Among the 8 patients who received placebo and experienced
ARAHEs, 4 (50%) had severe nocturnal hypoxemia (ie, SpO2 <75% for >30minutes), 1 (13%) had a
panic attack, 1 (13%) had nocturnal urinary incontinence, 1 (13%) had intolerable dyspnea sensation,
1 (13%) had nonsustained ventricular tachycardia during exercise, and 1 (13%) had a COPD
exacerbation. In 3 patients (38%), these ARAHEswere accompanied or followed by clinically relevant
AMS. The 1 patient (13%) experiencing an ARAHEwhile using NOT had a COPD exacerbation on the
day of descent from 2048m.
Daytime Evaluations
Daytime outcomes are presented in Table 3. After the first night at 2048m, patients with placebo
had higher AMS scores compared with 490m (mean [SD], 0.2 [0.5] vs 0.1 [0.1]; P = .01), increased
daytime sleepiness scores (mean [SD], 3.6 [1.9] vs 2.8 [1.4]; P = .03), and rated their subjective sleep
Figure 2. Effect of Altitude and Nocturnal Oxygen Therapy on the Apnea-Hypopnea Index (AHI)
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quality worse (mean [SD], 51% [23%] vs 64% [20%]; P = .002) (Table 3). With NOT, patients rated
their sleep quality better compared with placebo (difference after the first night, 9 percentage
points; 95% CI, 0 to 17 percentage points) (Table 3).
Compared with 490m, higher rated dyspnea score (mean [SD], 3.2 [1.9] vs 3.8 [2.5]; P = .02)
and a shorter 6-minute walk distance (mean [SD], 543 [89] m vs 486 [94] m; P < .001) were
observed at 2048mwith placebo. Receiving NOT did not change the 6-minute walk distance or
dyspnea score compared with placebo but lowered end-exercise systolic blood pressure (difference
after first night, −10mmHg; 95%CI, −18 to −2mmHg) and diastolic blood pressure (difference after
first night, −6mmHg; 95% CI, −11 to 0mmHg) (Table 3).
Arterial blood gas analysis in themorning after the first night at 2048m revealed higher pH
compared with 490m (mean [SD], 7.47 [0.03] vs 7.44 [0.02]; P < .001) and lower partial pressure of
arterial oxygen (PaO2; mean [SD], 7.9 [0.8] kPa vs 9.1 [0.9] kPa; P < .001) and partial pressure of
arterial carbon dioxide (PaCO2; mean [SD], 4.5 [0.5] kPa vs 5.3 [0.4] kPa; P < .001) with placebo. With
Table 2. Results of Sleep Studies in Per-Protocol Analysisa
Outcome
Mean (SD)




With nocturnal placebo With NOT
First night Second night First night Second night First night Second night
Time in bed, min 497 (29) 486 (25) 476 (60) 484 (49) 492 (25) −2 (−23 to 20) 16 (−5 to 37)
Nocturnal SpO2, % 92 (2) 86 (3)
b 87 (3)b 96 (2)b 96 (3)b 10 (9 to 11)c 9 (7 to 10)c
SpO2 <90%, % TIB 12.5 (19.0) 77.4 (27.7)
b 70.0 (30.5)b 1.2 (2.8)b 4.5 (20.6) −76.4 (−87.5 to −65.3)c −65.6 (−76.7 to −54.4)c
ODI, 1/h TIBd 9.3 (11.7) 40.0 (28.4)b 34.1 (24.4)b 4.1 (10.3) 4.2 (11.2) −35.9 (−44.4 to −27.5)c −29.9 (−38.3 to −21.4)c
Total AHI, 1/h TIB 19.7 (13.9) 36.1 (27.9)b 27.3 (22.6)b 14.3 (16.9) 10.4 (10.4)b −21.7 (−29.3 to −14.3)c −17.0 (−24.4 to −9.5)c
Obstructive AHI, 1/h TIB 17.7 (13.1) 9.3 (11.2)b 7.6 (8.8)b 9.0 (10.9)b 5.5 (6.9)b −0.3 (−3.6 to 3.0) −2.1 (−5.4 to 1.2)
Central AHI, 1/h TIB 2.1 (2.0) 26.8 (23.9)b 19.7 (19.5)b 5.3 (11.4) 4.8 (7.4) −21.5 (−28.3 to −14.7)c −14.9 (−21.7 to −8.1)c
Periodic breathing, % TIB 0.2 (0.6) 15.5 (16.6)b 12.1 (13.1)b 3.2 (8.5) 3.1 (5.5) −12.4 (−17.1 to −7.7)c −9.0 (−13.7 to −4.2)c
TcCO2, kPa 5.5 (0.7) 4.8 (0.4)
b 4.8 (0.4)b 4.9 (0.8)b 5.3 (0.7) 0.3 (−0.1 to 0.5) 0.4 (0.1 to 0.8)c
Heart rate, bpm 69 (10) 76 (12)b 74 (12)b 68 (12) 70 (10) −7 (−10 to −5)c −4 (−6 to −1)c
VES, 1/h TIB 10.2 (28.3) 14.5 (27.7) 18.8 (44.5) 9.7 (25.8) 6.4 (13.7) −4.8 (−14.9 to 8.4) −12.3 (−22.6 to −2.1)c
SVES, 1/h TIB 10.3 (18.2) 25.4 (75.3) 7.7 (14.7) 15.6 (39.5) 19.6 (44.9) −9.8 (−27.2 to 7.6) 12.3 (−5.3 to 29.9)
Total sleep time, min 400 (61) 349 (76)b NA 386 (71) NA 35 (9 to 61)c NA
Total AHI, 1/h TST 22.0 (15.8) 44.0 (35.8)b NA 16.9 (19.7) NA −27.1 (−36.6 to −17.6)c NA
Obstructive AHI, 1/h TST 20.4 (15.2) 11.6 (13.2)b NA 11.2 (12.5)b NA −0.5 (−4.7 to 3.7) NA
Central AHI, 1/h TST 1.6 (1.9) 32.4 (32.3)b NA 5.7 (13.7) NA −26.7 (−35.2 to −18.1)c NA
Nocturnal CTO, %e 64 (6) 59 (5)b NA 69 (6)b NA 9 (7 to 11)c NA
cODI, 1/h TIBf 0.8 (1.3) 4.2 (5.6)b NA 0.6 (1.1) NA −3.6 (−5.8 to −1.5)c NA
Sleep efficiency, % TIB 81 (11) 72 (15)b NA 78 (14) NA 7 (2 to 11)c NA
WASO, min 75.3 (49.3) 116.8 (67.8)b NA 86.3 (62.0) NA −30.0 (−52.2 to −7.9)c NA
Sleep latency, min 21.2 (24.1) 19.6 (16.0) NA 20.6 (15.2) NA 0.8 (−6.7 to 8.2) NA
Arousal index, /h 13.7 (8.8) 18.7 (16.2)b NA 13.8 (9.7) NA −4.6 (−9.2 to 0)c NA
NREM 1, % TST 29.9 (15.0) 33.0 (21.2) NA 25.5 (18.4) NA −7.4 (−14.0 to −0.8)c NA
NREM 2, % TST 40.6 (12.4) 42.0 (16.8) NA 45.6 (13.2) NA 3.6 (−1.6 to 8.9) NA
NREM 3 and 4, % TST 14.1 (6.7) 13.2 (10.1) NA 13.8 (8.9) NA 0.1 (−3.3 to 3.5) NA
REM, % TST 15.4 (4.3) 11.9 (6.8)b NA 15.1 (6.8) NA 3.2 (0.7 to 5.7)c NA
Abbreviations: AHI, apnea-hypopnea index; bpm, beats per minute; CTO, cerebral tissue
oxygenation; cODI, cerebral ODI; NA, not applicable; NOT, nocturnal oxygen therapy;
NREM, non–rapid eyemovement sleep; ODI, oxygen desaturation index; REM, rapid eye
movement sleep; SpO2, mean nocturnal arterial oxygen saturation by pulse oximetry;
SVES, supraventricular extra-beats; TcCO2, transcutaneous capnography; TIB, time in
bed; TST, total sleep time; VES, ventricular extra-beats; WASO, wake after sleep onset.
a In the first night at all locations, full polysomnography was performed; in the second
night, respiratory sleep studies were performed. Thus, sleep variables are not available
for second nights.
b P < .05 altitude vs 490m.
c P < .05 NOT vs placebo.
d ODI defined as greater than 3% dips in SpO2.
e CTOmeasured by near-infrared spectroscopy.
f cODI defined as greater than 3% dips in CTO.
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NOT, no changes in arterial blood gases were observed compared with placebo. Lung function and
psychomotor vigilance test reaction timewere not altered at 2048mwith placebo or NOT compared
with 490m.
Table 3. DaytimeMeasures for Per-Protocol Analysis
Outcome
Mean (SD)




With nocturnal placebo With NOT
Second day Third day Second day Third day Second day Third day
Questionnaire evaluation
AMSc 0.1 (0.1) 0.2 (0.5)a 0.1 (0.6) 0.1 (0.3) 0.1 (0.3) −0.1 (−0.2 to 0.1) 0 (−0.2 to 0.1)
Karolinska sleepiness score 2.8 (1.4) 3.6 (1.9)a 2.8 (1.4) 3.4 (1.8) 3.1 (1.8) −0.2 (−0.9 to 0.5) 0.4 (−0.3 to 1.0)
Subjective sleep quality visual analog
scale, %
64 (20) 51 (23)a 60 (20) 59 (20) 64 (23) 9 (0 to 17)b 3 (−5 to 12)
Estimated time spent awake at night, min 55 (50) 86 (71)a 70 (73) 68 (72) 56 (56) −18 (−48 to 12) −14 (−45 to 16)
Clinical examination and exercise performance
Weight, kg 70.4 (12.1) 70.4 (12.0) 70.5 (11.9) 70.4 (12.0) 70.9 (12.1) 0 (−0.6 to 0.6) 0.4 (−0.2 to 1.0)
At rest
Heart rate, bpm 68 (10) 74 (12)a 71 (13)a 69 (12) 68 (10) −4 (−7 to −2)b −3 (−5 to 0)b
BP, mm Hg
Systolic 130 (19) 133 (14) 129 (14) 130 (19) 124 (14)a −4 (−9 to 2) −5 (−10 to 1)
Diastolic 73 (10) 78 (10)a 74 (9) 78 (9)a 72 (9) 1 (−3 to 5) −2 (−6 to 1)
6MWT distance, m 543 (89) 486 (94)a 493 (97)a 480 (118)a 492 (107)a −7 (−24 to 11) −2 (−19 to 16)
At end of 6MWT
Borg CR10 dyspnea score 3.2 (1.9) 3.8 (2.5)a 3.9 (2.0)a 4.0 (2.6)a 4.0 (2.5)a 0.1 (−0.5 to 0.7) 0.1 (−0.5 to 0.7)
Heart rate, bpm 108 (21) 113 (18) 116 (20)a 113 (21) 117 (19)a 0 (−7 to 6) 2 (−5 to 8)
BP, mm Hg
Systolic 163 (33) 170 (32) 168 (31) 160 (30) 160 (28) −10 (−18 to −2)b −8 (−17 to 0)b
Diastolic 82 (13) 88 (17)a 89 (18)a 83 (11) 84 (11) −6 (−11 to 0)b −5 (−10 to 1)
Arterial blood gas analysis
pH 7.44 (0.02) 7.47 (0.03)a NA 7.47 (0.02)a NA 0.00 (−0.01 to 0.01) NA
PaCO2, kPa 5.3 (0.4) 4.5 (0.5)
a NA 4.5 (0.5)a NA 0 (−0.1 to 0.3) NA
PaO2, kPa 9.1 (0.9) 7.9 (0.8)
a NA 7.9 (0.9)a NA −0.1 (−0.4 to 0.1) NA
SaO2, % 94 (2) 90 (3)
a NA 90 (4)a NA 0 (−1 to 1) NA
Hemoglobin, g/dL 14.1 (1.2) 14.5 (1.2)a NA 14.6 (1.3)a NA 0 (−0.2 to 0.3) NA
Lung function
FEV1, L 1.7 (0.5) 1.7 (0.5) 1.8 (0.5)
a 1.7 (0.5) 1.8 (0.5)a 0 (0 to 0.1) 0 (−0.1 to 0.1)
FEV1, % predicted 63 (14) 61 (14) 66 (14)
a 64 (12) 66 (14)a 2 (−1 to 4) −1 (−3 to 1)
FVC, L 3.1 (0.7) 3.2 (0.8)a 3.3 (0.7)a 3.2 (0.8)a 3.2 (0.8) 0 (−0.1 to 0.1) −0.1 (−0.2 to 0)
FVC, % predicted 90 (12) 92 (16)a 95 (13)a 93 (15) 92 (13) 0 (−3 to 3) −3 (−6 to 0)b
FEV1/FVC, % 54 (12) 52 (11)
a 54 (9) 54 (10) 56 (10) 1 (0 to 3) 1 (−1 to 3)
TLCO adjusted for hemoglobin,
mL/mm Hg/min
5.8 (1.9) 6.0 (2.0)a 6.0 (2.0)a 6.2 (2.0)a 6.1 (2.1)a 0.1 (−0.1 to 0.3) 0 (−0.2 to 0.3)
TLCO adjusted for hemoglobin,
% predicted
71 (20) 74 (21) 74 (21) 77 (21) 76 (21) 2 (−1 to 5) 0 (−3 to 3)
TLCO adjusted for hemoglobin and
altitude, % predicted
69 (20) 66 (19) 67 (19) 68 (19) 68 (20) 2 (−1 to 4) 0 (−3 to 3)
Vigilance
PVT reaction time, ms 268 (47) 262 (42) 258 (41) 261 (52) 271 (45) −1 (−14 to 12) 13 (0 to 26)b
Abbreviation: 6MWT, 6-minute walk test; AMSc, acute mountain sickness score; BP,
blood pressure; bpm, beats per minute; CR10, category ratio anchored at the number 10;
FEV1, forced expiratory volume in the first second of expiration; FVC, forced vital
capacity; NA, not applicable; NOT, nocturnal oxygen therapy; PaCO2, partial pressure of
arterial carbon dioxide; PaO2, partial pressure of arterial oxygen; PVT, psychomotor
vigilance test; SaO2, arterial oxygen saturation; TLco, diffusing capacity for carbon
monoxide.
SI conversion factor: To convert hemoglobin to grams per liter, multiply by 10.
a P < .05 altitude vs 490m.
b P < .05 NOT vs placebo.
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Discussion
We performed a randomized, placebo-controlled, crossover trial to evaluate the effect of NOT on
nocturnal breathing, sleep, and daytime performance in lowlanders with grade 2 to 3 COPD staying
for 2 days and nights at an altitude of 2048m. Exposure to high altitude induced arterial and cerebral
hypoxemia, breathing instability, worsening of sleep structure, and subjective sleep quality.
Furthermore, 26% of patients using placebo experienced ARAHEs requiring medical treatment or
descent. We found that NOT prevented hypoxemia, attenuated sleep apnea, improved sleep
structure and subjective sleep quality at high altitude, and reduced the incidence of ARAHEs by 85%
compared with placebo.
In a previous trial among 40 patients with moderate to severe COPD (median FEV1, 59%
predicted) ascending to 2590m,7 nocturnal hypoxemia and sleep apnea were similar compared with
the current findings (median nocturnal SpO2, 85% vs 86%; AHI, 39.5/h vs 36.1/h time in bed). In the
cited trial,7 half of the patients had an intermediate 2-day altitude stay at 1650mbefore ascending to
2590m. Therefore, acclimatizationmight have dampened the altitude effect.7 At 2590m, a 24%
incidence of ARAHEs was reported,4 confirming the susceptibility of patients with COPD to
hypobaric hypoxia. For comparison, at altitudes up to 2590m, adverse events requiring medical
treatment or descent were uncommon in healthy volunteers or in patients with obstructive sleep
apnea syndrome.3,24 Randomized, controlled studies with shorter exposure (ie, a few hours) to
hypobaric hypoxia, such as during airplane travel, showed decrements in PaO2 and exercise capacity,
but patients otherwise remained asymptomatic.25-27However, a cross-sectional study28 has shown
that 12.1% of all in-flight emergencies are due to respiratory-related symptoms, some resulting in
admission to the hospital. In 49.9% of in-flight medical emergencies, supplemental oxygen was
administered.28 Therefore, the British Thoracic Society recommends in-flight oxygen therapy in
patients with very severe COPD (ie, FEV1 30% predicted) when PaO2 is lower than 6.67 kPa or SaO2
is lower than 85%during a hypoxia altitude simulation test (ie, breathing fraction of inspired oxygen,
0.15; equivalent to 2438m for 20minutes).29 However, the accuracy of the hypoxia altitude
simulation test in predicting symptoms and level of hypoxemia in patients with COPD during flights
is low,26 and the test has never been validated for prediction of adverse effects during altitude travel.
Patients in the current trial, who would not have required a hypoxia altitude simulation test before
traveling by airplane according to the guidelines (FEV1 30% predicted), had daytime PaO2
measured 18 hours after arrival at 2048m between 5.7 to 9.0 kPa and SaO2 between 79% to 95%,
indicating that 5 of 31 patients (16%) with moderate to severe COPD would have fulfilled the British
Thoracic Society criteria for oxygen supplementation at an altitude of 2048m.
Nocturnal hypoxemia and AHI in the current patients with COPD at 2048m (mean [SD] SpO2,
86% [3%]; AHI, 36.1/h [27.9/h] with placebo) were worse compared with corresponding values in 51
healthy volunteers at 2590m (median [interquartile range {IQR}] SpO2, 90% [89%-91%]; median
[IQR] AHI, 13.1/h [6.7/h-32.1/h]).3 Compared with patients with obstructive sleep apnea at 2590 m
(median [IQR], SpO2, 85% [83%-88%]; median [IQR] AHI, 86.2/h [67.2/h-103.1/h]),
24 patients with
COPD had lower AHI but similar hypoxemia at 2048 m, probably because of airflow obstruction,
ventilation or perfusionmismatch, and diffusion limitation causingmild hypoxemia already at 490m.
In terms of ventilatory control theory, it is interesting to note that the degree of altitude-induced
deterioration of breathing stability reflected in the AHI in patients with COPD fell between the
modest AHI increase in healthy individuals and themajor increase in patients with obstructive sleep
apnea syndrome in the cited studies.3,24 Presumably, mechanical ventilatory constraints and
ventilatory inefficiency that reduces the plant gain of respiratory control in patients with COPD
prevented an excessive increase in the AHI to the degree observed in patients with obstructive sleep
apnea. Conversely, a relatively enhanced neural respiratory drive in patients with COPD30 in the
presence of hypoxia-induced chemoreceptor stimulation and altitude-induced pulmonary
hypertension promoted greater ventilatory instability compared with healthy individuals.31,32
Exploratory analysis revealed that low altitude baseline AHI and nocturnal SpO2were independently
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associated with high altitude sleep-disordered breathing and nocturnal hypoxemia (eTable 3 and
eTable 4 in Supplement 2), suggesting that overnight oximetry at low altitudemight serve as a
screening tool to identify patients susceptible to sleep disturbed breathing at high altitude.
The reduction of the AHI by NOTwas quite pronounced, with even lower values at 2048m than
at 490m (Table 2). It was associated with an overcorrection of nocturnal SpO2 by NOT, greater than
values recorded at 490m (mean [SD], 96% [2%] vs 92% [2%]). Thus, a combined, stabilizing effect
of oxygen and of acclimatization on control of breathing might have very effectively reduced the
AHI, particularly on the second night at high altitude.
Improvements in sleep structure with NOTwere reflected by a higher sleep efficiency, a lower
arousal index, a lower percentage of superficial non–rapid eye movement sleep stages 1 and 2, and
more rapid eyemovement sleep (Table 2). The improvements may have been the result of improved
oxygenation and reduced AHI in patients with COPDwho received NOT. Subjective sleep quality
improved by 9 percentage points after the first night with NOT at 2048m, similar to the difference
of 10 percentage points found to be clinically important in patients with insomnia.33 Systolic and
diastolic blood pressure at the end of the 6-minute walk test were improved the day after NOT,
possibly related to less nocturnal sympathetic activity, as indicated by a lower nocturnal heart rate
and a reduced incidence of ventricular extra-beats.
Despite improvements in sleep structure and breathing and better subjective sleep quality with
NOT at 2048m, similar exercise capacity, cognitive performance, and arterial blood gases were
observed as with placebo (Table 3). These findings suggest no persistent, measurable effect of NOT
on these outcomes.
In addition to the directly measurable effect of NOT on hypoxemia, we speculate that it
prevented the hypoxia-induced activation of systemic inflammatory pathways, excessive
hyperventilation, and sympathetic overexcitation. This might explain favorable effects of NOT on
ARAHE other than just hypoxemia including AMS, COPD exacerbations, and intolerable dyspnea.
Limitations
This study has limitations. This trial included patients with moderate to severe COPD staying for 2
days at 2048m; therefore, no extrapolation should be drawn to patients with mild or very severe
COPD, higher altitudes, or longer altitude exposures. This study applied 3 L/min NOT through a nasal
cannula to improve hypoxemia and sleep-disturbed breathing. This intervention improved SpO2 and
AHI beyond the values obtained at 490m, suggesting that 2 L/min NOTmight be sufficient during
altitude travel in certain patients. The a priori definition of severe hypoxemia (ie, SpO2 <75% for >30
minutes at any time during the stay at high altitude), an ARAHE criterion that required study
withdrawal and treatment with oxygen, was based on safety concerns. Although severe hypoxemia
may not necessarily result in a relevant adverse event when left untreated, in the absence of
scientific evidence we considered it as clinically reasonable and ethically well justified not to expose
patients with COPD (some of whom also had cardiovascular disease) to more severe and
prolonged hypoxia.
Conclusions
In this randomized, placebo-controlled, crossover trial among lowlanders with moderate to severe
COPD ascending for 2 days to 2048 m, we found that altitude exposure was associated with
considerable nocturnal hypoxemia as well as breathing and sleep disturbances. The current trial
showed that NOT is a highly effective preventive therapy, which not only improved nocturnal SpO2,
altitude-induced sleep apnea, sleep efficiency, and subjective sleep quality but also prevented
ARAHEs. The fact thatmore than a quarter of the patients with COPD experienced ARAHEs illustrates
that a considerable proportion of patients with grade 2 to 3 COPD is not fit to travel to high altitudes
without appropriate precautions or preventive NOT.
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